Group 1: Industry Outlook - The medical device industry, particularly in pain management and upper airway management, has significant growth potential due to increasing surgical procedures and pain management needs. In 2023, there were approximately 96.39 million surgical procedures in China, with 70%-80% of postoperative patients experiencing severe pain [4][5]. - The current pain relief rate for childbirth in China is about 30%, compared to 85%-98% in developed countries, indicating substantial market potential for growth [4]. - The prevalence of allergic rhinitis in China is 17.6%, and chronic sinusitis is around 8%, suggesting a rising demand for nasal treatments [5]. Group 2: Company Performance - In 2024, the company reported total revenue of 403.80 million yuan, a decrease of 4.35% from the previous year, while net profit attributable to shareholders was 10.80 million yuan, an increase of 30.49% [6][8]. - The pain management segment generated revenue of 248.43 million yuan, reflecting a growth of 12.42%, while the upper airway management segment saw a decline of 32.61%, with revenue of 123.38 million yuan [8]. Group 3: Future Growth Strategies - The company aims to develop an ecosystem focused on single disease management, leveraging pain management and upper airway management as foundational areas while exploring innovations in brain-computer interfaces and perioperative recovery [7]. - Future initiatives include the application of artificial intelligence for product development in pain assessment, sleep diagnostics, and brain health evaluations, which are expected to drive long-term growth [7].